10/12/21 8:01 AMNasdaq : AEMD covid-19low floatAethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases ofRHEA-AIneutral
09/30/21 8:02 AMNasdaq : AEMD, PPD low floatAethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical ProgramsAethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract researchRHEA-AIneutral
09/07/21 8:01 AMNasdaq : AEMD conferenceslow floatAethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceAethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23 rd Annual Global InvestmentRHEA-AIneutral
08/09/21 4:15 PMNasdaq : AEMD earningslow floatAethlon Medical Announces First Quarter Financial Results and Provides Corporate UpdateAethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update onRHEA-AIneutral
07/29/21 1:32 PMNasdaq : AEMD earningslow floatAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday,RHEA-AIneutral
06/24/21 4:15 PMNasdaq : AEMD earningslow floatAethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate UpdateAethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2021 and provided an update onRHEA-AIneutral
06/21/21 3:27 PMNasdaq : AEMD earningslow floatAethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET onRHEA-AIneutral
06/10/21 9:10 AMNasdaq : AEMD offeringlow floatAethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered directRHEA-AIneutral
06/03/21 8:01 AMNasdaq : AEMD covid-19low floatAethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with theRHEA-AIneutral
03/01/21 8:02 AMNasdaq : AEMD conferenceslow floatAethlon Medical to Participate in Two Upcoming Healthcare Investor ConferencesAethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and theRHEA-AIneutral